Evidence map›Paper›PMID 29848570›Full record

ArticleClinical cancer research : an official journal of the American Association for Cancer Research2018

Radium-223 Dichloride in Combination with Vascular Endothelial Growth Factor-Targeting Therapy in Advanced Renal Cell Carcinoma with Bone Metastases.

Rana R McKay, Dominick Bossé, Kathryn P Gray, M Dror Michaelson, Katherine Krajewski, Heather A Jacene, Meghara Walsh, Joaquim Bellmunt, Mark Pomerantz, Lauren C Harshman and 1 more

Open access · bronzeAbstract readClinical Trial, Phase I
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical cancer research : an official journal of the American Association for Cancer Research, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed, 1 pooled it
2.9field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 1 synthesis or guideline pooled it, 31 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Trial
  4. Radium - from discovery to the present day - narrative review.Clinical and experimental medicine · 2026
    Review
  5. Review
  6. Review
  7. Article
  8. Article
  9. Review
  10. Article
  11. Review
  12. Review
  13. Review
  14. Review
  15. Article
  16. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 1 country.

Rana R McKay *Moores Cancer Center, UC San Diego Health, San Diego, California. toni_choueiri@dfci.harvard.edu.
Dominick Bossé *Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts.ORCID 0000-0003-2992-5632
Kathryn P GrayDepartment of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Harvard T.H. Chan School of Public Health, Boston, Massachusetts.
M Dror MichaelsonGenitourinary Cancer Center, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts.
Katherine KrajewskiBrigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.
Heather A JaceneBrigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.
Meghara WalshDepartment of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Harvard T.H. Chan School of Public Health, Boston, Massachusetts.
Joaquim BellmuntLank Center for Genitourinary Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts.
Mark PomerantzLank Center for Genitourinary Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts.
Lauren C HarshmanLank Center for Genitourinary Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts.
Toni K ChoueiriLank Center for Genitourinary Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts. toni_choueiri@dfci.harvard.edu.
Brigham and Women's Hospital · USDana-Farber Cancer Institute · USMassachusetts General Hospital · USUC San Diego Health System · US

Funding

Treating the P13-Kinase/AKTP50CA101942 · NCI · BETH ISRAEL DEACONESS MEDICAL CENTER · PI Wanling Xie · 2003 to 2026
$53.4M
Genetic Predictors of Response to mTOR inhibitors in advanced Renal CancerR21CA191687 · NCI · DANA-FARBER CANCER INST · PI CHOUEIRI, TONI, KWIATKOWSKI, DAVID J. · 2015 to 2016
$421k
NCI NIH HHS P50 CA101942
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

AgedAntineoplastic Combined Chemotherapy ProtocolsBone NeoplasmsBone RemodelingCarcinoma, Renal CellCombined Modality TherapyDose-Response Relationship, DrugDrug-Related Side Effects and Adverse ReactionsFemaleHumansIndazolesMaleMiddle AgedNeoplasm MetastasisPyrimidinesRadioisotopesIndazolespazopanibPyrimidinesRadioisotopesRadiumradium Ra 223 dichlorideSorafenibSulfonamidesVascular Endothelial Growth Factor AVEGFA protein, human

Identifiers

PMID29848570
PMCPMC6688176
OpenAlexW2806400341

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.